How Inter Partes Review Impacts Hatch-Waxman Exclusivity
The new inter partes review proceedings available under the America Invents Act present new and unique strategic advantages for generic drug challengers in Hatch-Waxman cases.[1] However, the Hatch-Waxman framework hinges on...To view the full article, register now.
Already a subscriber? Click here to view full article